Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

CS-747 reported to be a safe antiplatelet therapy in patients undergoing PCI

Sep. 6, 2004

AxyS (Celera Genomics) presents novel factor VIIa inhibitors

Sep. 6, 2004

Antithrombotic effects of novel coagulation factor Xa inhibitor

Sep. 3, 2004

GlaxoSmithKline acquires Fraxiparine, Fraxodi and Arixtra

Sep. 3, 2004

Janssen researchers present new PAR-1 antagonists

Sep. 3, 2004

New factor Xa inhibitors in early development at Lilly

Sep. 1, 2004

Discovery of Bay-59-7939 discussed at ACS meeting

Aug. 26, 2004

Saratin shows antithrombotic effects in human atherosclerotic plaques

Aug. 26, 2004

Boehringer Ingelheim claims novel factor Xa inhibitors

Aug. 24, 2004

Discovery of potent himbacine-based thrombin receptor antagonist

Aug. 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...